Effects of ketamine use on psychotic disorders and symptoms in male, methamphetamine-dependent subjects

References

• World Drug Report. United nations office on drugs and crime. United Nations publication, Sales No.  E.16.XI.7; 2016.
   Google Scholar
• Annual Report on Drug Control in China. National Narcotic Control Commission (NNCC). Beijing: Ministry of Public Security; 2004.
   Google Scholar
• Annual Report on Drug Control in China. National Narcotic Control Commission (NNCC). Beijing: Ministry of Public Security; 2017.
   Google Scholar
• Hides L, Dawe S, McKetin R, Kavanagh DJ, Young RM, Teesson M, Saunders JB. Primary and substance-induced psychotic disorders in methamphetamine users. Psychiatry Res. 2015;226(1):91–96. doi:10.1016/j.psychres.2014.11.077.
   PubMed Web of Science ®Google Scholar
• Frohlich J, Van Horn JD. Reviewing the ketamine model for schizophrenia. J Psychopharmacol. 2014;28(4):287–302. doi:10.1177/0269881113512909.
   PubMed Web of Science ®Google Scholar
• Moghaddam B, Krystal JH. Capturing the angel in “angel dust”: twenty years of translational neuroscience studies of NMDA receptor antagonists in animals and humans. Schizophr Bull. 2012;38(5):942–49. doi:10.1093/schbul/sbs075.
   PubMed Web of Science ®Google Scholar
• Fan N, Xu K, Ning Y, Rosenheck R, Wang D, Ke X, Ding Y, Sun B, Zhou C, Deng X, et al. Profiling the psychotic, depressive and anxiety symptoms in chronic ketamine users. Psychiatry Res. 2016;237:311–15. doi:10.1016/j.psychres.2016.01.023.
   PubMed Web of Science ®Google Scholar
• Dillon P, Copeland J, Jansen K. Patterns of use and harms associated with nonmedical ketamine use. Drug Alcohol Depend. 2003;69(1):23–28.
   PubMed Web of Science ®Google Scholar
• Carter JL, Strang J, Frissa S, Hayes RD, Team SES, Hatch SL, Hotopf M. Comparisons of polydrug use at national and inner city levels in England: associations with demographic and socioeconomic factors. Ann Epidemiol. 2013;23(10):636–45. doi:10.1016/j.annepidem.2013.07.012.
   PubMed Web of Science ®Google Scholar
• Dong H, Yang M, Liu L, Zhang C, Liu M, Shen Y, Liu H, Hao W. Comparison of demographic characteristics and psychiatric comorbidity among methamphetamine-, heroin- and methamphetamine-heroin co dependent males in Hunan, China. BMC Psychiatry. 2017;17(1):183.
   PubMedGoogle Scholar
• Moss HB, Chen CM, Yi HY. Early adolescent patterns of alcohol, cigarettes, and marijuana polysubstance use and young adult substance use outcomes in a nationally representative sample. Drug Alcohol Depend. 2014;136:51–62. doi:10.1016/j.drugalcdep.2013.12.011.
   PubMed Web of Science ®Google Scholar
• Quek LH, Chan GC, White A, Connor JP, Baker PJ, Saunders JB, Kelly AB. Concurrent and simultaneous polydrug use: latent class analysis of an Australian nationally representative sample of young adults. Front Public Health. 2013;1:61. doi:10.3389/fpubh.2013.00061.
   PubMedGoogle Scholar
• Zhang Y, Lu C, Zhang J, Hu L, Song H, Li J, Kang L. Gender differences in abusers of amphetamine-type stimulants and ketamine in southwestern China. Addict Behav. 2013;38(1):1424–30. doi:10.1016/j.addbeh.2012.06.024.
   PubMed Web of Science ®Google Scholar
• Zhang Y, Xu Z, Zhang S, Desrosiers A, Schottenfeld RS, Chawarski MC. Profiles of psychiatric symptoms among amphetamine type stimulant and ketamine using inpatients in Wuhan, China. J Psychiatr Res. 2014;53:99–102. doi:10.1016/j.jpsychires.2014.02.010.
   PubMed Web of Science ®Google Scholar
• Evans EA, Grella CE, Washington DL, Upchurch DM. Gender and race/ethnic differences in the persistence of alcohol, drug, and poly-substance use disorders. Drug Alcohol Depend. 2017;174:128–36. doi:10.1016/j.drugalcdep.2017.01.021.
   PubMed Web of Science ®Google Scholar
• Goldstein RB, Dawson DA, Chou SP, Grant BF. Sex differences in prevalence and comorbidity of alcohol and drug use disorders: results from wave 2 of the National Epidemiologic Survey on alcohol and related conditions. J Stud Alcohol Drugs. 2012;73(6):938–50. doi:10.15288/jsad.2012.73.938.
   PubMed Web of Science ®Google Scholar
• First M, Spitzer R, Gibbon M, Williams J. Structured clinical interview for DSM-IV-TR axis I disorders. New York: Biometrics Research Department, New York State Psychiatric Institute; 2003.
   Google Scholar
• Phillips MR, Zhang J, Shi Q, Song Z, Ding Z, Pang S, Li X, Zhang Y, Wang Z. Prevalence, treatment, and associated disability of mental disorders in four provinces in China during 2001-05: an epidemiological survey. Lancet. 2009;373(9680):2041–53. doi:10.1016/S0140-6736(09)60660-7.
   PubMed Web of Science ®Google Scholar
• Mezzich JE, Kirmayer LJ, Kleinman A, Fabrega H Jr., Parron DL, Good BJ, Lin KM, Manson SM. The place of culture in DSM-IV. J Nerv Ment Dis. 1999;187(8):457–64.
   PubMed Web of Science ®Google Scholar
• Ranstam J. Multiple P-values and Bonferroni correction. Osteoarthritis Cartilage. 2016;24(5):763–64. doi:10.1016/j.joca.2016.01.008.
   PubMed Web of Science ®Google Scholar
• Krystal JH, Perry EB Jr., Gueorguieva R, Belger A, Madonick SH, Abi-Dargham A, Cooper TB, Macdougall L, Abi-Saab W, D’Souza DC. Comparative and interactive human psychopharmacologic effects of ketamine and amphetamine: implications for glutamatergic and dopaminergic model psychoses and cognitive function. Arch Gen Psychiatry. 2005;62(9):985–94. doi:10.1001/archpsyc.62.9.985.
   PubMed Web of Science ®Google Scholar
• Kegeles LS, Abi-Dargham A, Zea-Ponce Y, Rodenhiser-Hill J, Mann JJ, Van Heertum RL, Cooper TB, Carlsson A, Laruelle M. Modulation of amphetamine-induced striatal dopamine release by ketamine in humans: implications for schizophrenia. Biol Psychiatry. 2000;48(7):627–40.
   PubMed Web of Science ®Google Scholar
• Ujike H, Sato M. Clinical features of sensitization to methamphetamine observed in patients with methamphetamine dependence and psychosis. Ann N Y Acad Sci. 2004;1025:279–87. doi:10.1196/annals.1316.035.
   PubMed Web of Science ®Google Scholar
• London ED, Kohno M, Morales AM, Ballard ME. Chronic methamphetamine abuse and corticostriatal deficits revealed by neuroimaging. Brain Res. 2015;1628(Pt A):174–85. doi:10.1016/j.brainres.2014.10.044.
   PubMed Web of Science ®Google Scholar
• Iyo M, Sekine Y, Mori N. Neuromechanism of developing methamphetamine psychosis: a neuroimaging study. Ann N Y Acad Sci. 2004;1025:288–95. doi:10.1196/annals.1316.036.
   PubMed Web of Science ®Google Scholar
• Orser BA, Pennefather PS, MacDonald JF. Multiple mechanisms of ketamine blockade of N-methyl-D-aspartate receptors. Anesthesiology. 1997;86(4):903–17.
   PubMed Web of Science ®Google Scholar
• Quibell R, Prommer EE, Mihalyo M, Twycross R, Wilcock A. Ketamine*. J Pain Symptom Manage. 2011;41(3):640–49. doi:10.1016/j.jpainsymman.2011.01.001.
   PubMed Web of Science ®Google Scholar
• Ke JJ, Chen HI, Jen CJ, Kuo YM, Cherng CG, Tsai YP, Ho M-C, Tsai C-W, Yu L. Mutual enhancement of central neurotoxicity induced by ketamine followed by methamphetamine. Toxicol Appl Pharmacol. 2008;227(2):239–47. doi:10.1016/j.taap.2007.10.017.
   PubMed Web of Science ®Google Scholar
• Pu C, Vorhees CV. Protective effects of MK-801 on methamphetamine-induced depletion of dopaminergic and serotonergic terminals and striatal astrocytic response: an immunohistochemical study. Synapse. 1995;19(2):97–104. doi:10.1002/syn.890190205.
   PubMed Web of Science ®Google Scholar
• Sonsalla PK, Nicklas WJ, Heikkila RE. Role for excitatory amino acids in methamphetamine-induced nigrostriatal dopaminergic toxicity. Science. 1989;243(4889):398–400.
   PubMed Web of Science ®Google Scholar